This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages)(Learn how and when to remove this template message)
Fertility medication, better known as fertility drugs, are drugs which enhance reproductive fertility. For women, fertility medication is used to stimulate follicle development of the ovary. There are currently very few fertility medication options available for men.
The main techniques involving fertility medication in females are:
- Ovulation induction, with the aim of producing one or two ovulatory follicles for fertilization by sexual intercourse or artificial insemination
- Controlled ovarian hyperstimulation, which is generally part of in vitro fertilization, and the aim is generally to develop multiple follicles (optimally between 11 and 14 antral follicles measuring 2–8 mm in diameter), followed by transvaginal oocyte retrieval, co-incubation, followed by embryo transfer of a maximum of two embryos at a time.
- Final maturation induction of follicles, also triggering a predictable time of ovulation.
Either Gonadotropin-releasing hormone (GnRH) or any Gonadotropin-releasing hormone agonist (i.e. Lupron) may be used. GnRH stimulates the release of gonadotropins (LH and FSH) from the anterior pituitary in the body.
Clomiphene (trademarked as Clomid) is a selective estrogen receptor modulator (SERM). It is the most widely used fertility drug. It is used in ovulation induction by inhibiting the negative feedback of estrogen at the hypothalamus. As the negative feedback of estrogen is inhibited, the hypothalamus secretes GnRh which in turn stimulates the anterior pituitary to secrete LH and FSH which help in ovulation.
Although primarily a breast cancer treatment, aromatase inhibitors are also used in ovulation induction, probably through a mechanism similar to clomiphene. Aromatase inhibitors will decrease the amount of testosterone converted to estradiol. Less estradiol circulating in the body will decrease the negative feedback at the level of the hypothalamus and result in sustained FSH secretion. More FSH will be available to stimulate the ovary and mature multiple follicles for ovulation. This is a common fertility treatment to treat women with PCOS.
For example, the so-called menotropins consist of LH and FSH extracted from human urine from menopausal women. There are also recombinant variants which are created by inserting the DNA coding for it into bacteriae. The bacterial DNA is then called Recombinant DNA. Examples of recombinant FSH are Follistim and Gonal F, while Luveris is a recombinant LH.
Human chorionic gonadotropinEdit
Human chorionic gonadotropin (hCG), also known as the “hormone of pregnancy” is a hormone that is normally produced during pregnancy and plays an integral role throughout reproduction. It is crucial in maintaining pregnancy, from the stages of placentation through to early embryo development. hCG is also used in assisted reproductive techniques as it can be used to replace Luteinizing Hormone (LH) in final maturation induction.
The use of fertility drugs is highly correlated with other ovarian cancer risk factors which complicates the direct contribution of the fertility drugs to ovarian cancer. Numerous studies indicate the risk of developing ovarian cancer as a result of fertility drugs is insignificant, but long-term exposure to fertility drugs may require further studies to determine their role in ovarian tumors and other health risks. Estrogen antagonists and gonadotropins may stimulate multiple follicles and other ovarian hormones leading to multiple birth and possible ovarian hyperstimulation syndrome.
Development of ovarian hyperstimulation syndrome (OHSS) is dependent on the administration of human chorionic gonadotropin (hCG) and is mediated through vascular endothelial growth factor (VEGF). OHSS is characterized as cystic enlargement of the ovaries. Multiple birth is especially deleterious due to compounding risks including premature delivery and low birthweight, pre-eclampisa, and increased risk of neonatal mortality. While triplet births have been declining in ART, multiple births remain over 50% of births from IVF. However, there are limitations to this date, as 4% to 8% IVF clinics to do not report their data to the CDC.
- Drobnis, Erma Z; Nangia, Ajay K (2017). Impacts of Medications on Male Fertility. Cham, Switzerland: Palgrave Macmillan. ISBN 978-3-319-69535-8. Retrieved 23 February 2019.
- Antral Follicle Counts, Resting Follicles, Ovarian Volume and Ovarian Reserve. Testing of egg supply and predicting response to ovarian stimulation drugs Advanced Fertility Center of Chicago. Retrieved on October 2, 2009
- Fertility: assessment and treatment for people with fertility problems. NICE clinical guideline CG156 - Issued: February 2013
- Stute, Petra; Birkhauser, Martin (2015). "Selective estrogen receptor modulators (SERM)/Selektive Ostrogenrezeptormodulatoren (SERM)". Gynakologische Endokrinologie. 13 (2): 126. doi:10.1007/s10304-015-0003-9.
- Badawy A, Abdel Aal I, Abulatta M (September 2009). "Clomiphene citrate or letrozole for ovulation induction in women with polycystic ovarian syndrome: a prospective randomized trial". Fertility and Sterility. 92 (3): 849–52. doi:10.1016/j.fertnstert.2007.02.062. PMID 17582406.
- Scwab, Manfred (2008). Encyclopedia of Cancer - Gonadatropins. Berlin, Heidelberg: Springer. ISBN 978-3-642-16483-5. Retrieved 23 February 2019.
- Menotropins at the US National Library of Medicine Medical Subject Headings (MeSH)
- Leão Rde B, Esteves SC (2014). "Gonadotropin therapy in assisted reproduction: an evolutionary perspective from biologics to biotech". Clinics (Sao Paulo, Brazil). 69 (4): 279–93. doi:10.6061/clinics/2014(04)10. PMID 24714837.
- Diergaarde B, Kurta ML (June 2014). "Use of fertility drugs and risk of ovarian cancer". Current Opinion in Obstetrics & Gynecology. 26 (3): 125–9. doi:10.1097/GCO.0000000000000060. PMC 4217689. PMID 24752005.
- Kumar P, Sait SF, Sharma A, Kumar M (May 2011). "Ovarian hyperstimulation syndrome". Journal of Human Reproductive Sciences. 4 (2): 70–5. doi:10.4103/0974-1208.86080. PMC 3205536. PMID 22065820.
- Workshop Group, T. E. C. (August 2000). "Multiple gestation pregnancy. The ESHRE Capri Workshop Group". Human Reproduction (Oxford, England). 15 (8): 1856–64. doi:10.1093/humrep/15.8.1856. PMID 10920117.
- Schieve LA, Peterson HB, Meikle SF, Jeng G, Danel I, Burnett NM, Wilcox LS (November 1999). "Live-birth rates and multiple-birth risk using in vitro fertilization". JAMA. 282 (19): 1832–8. doi:10.1001/jama.282.19.1832. PMID 10573274.